DRI
63
-3
HAL
54
4
YUM
58
2
SE
54
5
BEN
57
2
BRK.B
40
7
NI
67
2
PFG
55
2
HIG
70
2
KSS
58
-4
OKE
65
3
BMY
78
2
AMG
82
5
INTC
40
-3
SYK
35
4
BF.B
39
-3
KLAC
75
3
AXP
74
4
TGT
50
-7
VIX
19
-6
DRI
63
-3
HAL
54
4
YUM
58
2
SE
54
5
BEN
57
2
BRK.B
40
7
NI
67
2
PFG
55
2
HIG
70
2
KSS
58
-4
OKE
65
3
BMY
78
2
AMG
82
5
INTC
40
-3
SYK
35
4
BF.B
39
-3
KLAC
75
3
AXP
74
4
TGT
50
-7
VIX
19
-6
Financhill
Back

Ernexa Therapeutics, Inc. 10K Form

Sell
27

ERNA
Ernexa Therapeutics, Inc.

Last Price:
$1.27
Seasonality Move:
3.2%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive ERNA News And Ratings

See the #1 stock for the next 7 days that we like better than ERNA

ERNA Financial Statistics

Sales & Book Value

Annual Sales: $582K
Cash Flow: $-1.3M
Price / Cash Flow: 0
Annual Sales: $0.45
Price / Book: 2.64

Profitability

EPS (TTM): -2.59550
Net Income (TTM): $-18.3M
Gross Margin: $-1.2M
Return on Equity: 0%
Return on Assets: -288.35%

Ernexa Therapeutics, Inc. Earnings Forecast

Key Ernexa Therapeutics, Inc. Financial Ratios

  • The Gross Profit Margin over the past 31 years for ERNA is -197.94%.
  • The Selling, General & Administrative Expenses for ERNA have been equal to 2,256.36% of Gross Profit Margin.
  • The Research & Development expenses have been 791.07% of Revenue.
  • The Net Earning history of ERNA is -7,652.75% of Total Revenues.
  • Per Share Earnings over the last 31 years have been positive in 12 years.

Ernexa Therapeutics, Inc. Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biotechnology
Sector: Health Care
Current Symbol: ERNA
Website: ernexatx.com

Debt

Debt-to-Equity Ratio: 0.15
Current Ratio: 1.58
Quick Ratio: 1.42

Price-to-Earnings

Trailing P/E Ratio: 0
Forward P/E Ratio: 0

ERNA Technical Analysis vs Fundamental Analysis

Sell
27
Ernexa Therapeutics, Inc. (ERNA) is a Sell

Is Ernexa Therapeutics, Inc. a Buy or a Sell?